



News Release

Suven's Income at Rs. 1998 Mn; PAT at Rs. 388 Mn for the quarter ended June 2018

HYDERABAD, INDIA (14 Aug' 2018) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders and Contract Research and Manufacturing Services (CRAMS) today announced its un-audited financial results for the quarter ending 30th June 2018. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 14th Aug 2018 at Hyderabad.

Financial Highlights for the 1st Quarter ended June' 2018: (QoQ)

Growth in revenue	INR 1998 Mn vs. INR 2229 Mn - Down by 10.39%
Growth in PAT	INR 388 Mn vs. INR 623 Mn - Down by 37.77%
Growth in EBIDTA	INR 664 Mn vs. INR 1005 Mn - Down by 33.95%

Financial Highlights (comparison with same quarter, previous year):

Growth in revenue	INR 1998 Mn vs. INR 1466 Mn - Up by 36.24%
Growth in PAT	INR 388 Mn vs. INR 295 Mn - Up by 31.23%
Growth in EBIDTA	INR 664 Mn vs. INR 509 Mn - Up by 30.35%

Suven's thrust on innovative R&D in Drug Discovery continues with a spending of Rs 160 Mn (8% on revenue) for the quarter ended 30th June 2018.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained, if any, in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;